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Abstract
The Hastings Center, a bioethics research institute, is holding a series of 5 workshops to examine
the controversies surrounding the use of medication to treat emotional and behavioral
disturbances in children. These workshops bring together clinicians, researchers, scholars, and
advocates with diverse perspectives and from diverse fields. Our first commentary in CAPMH,
which grew out of our first workshop, explained our method and explored the controversies in
general. This commentary, which grows out of our second workshop, explains why informed
people can disagree about ADHD diagnosis and treatment. Based on what workshop participants
said and our understanding of the literature, we make 8 points. (1) The ADHD label is based on
the interpretation of a heterogeneous set of symptoms that cause impairment. (2) Because
symptoms and impairments are dimensional, there is an inevitable "zone of ambiguity," which
reasonable people will interpret differently. (3) Many other variables, from different systems and
tools of diagnosis to different parenting styles and expectations, also help explain why behaviors
associated with ADHD can be interpreted differently. (4) Because people hold competing views
about the proper goals of psychiatry and parenting, some people will be more, and others less,
concerned about treating children in the zone of ambiguity. (5) To recognize that nature has
written no bright line between impaired and unimpaired children, and that it is the responsibility of
humans to choose who should receive a diagnosis, does not diminish the significance of ADHD. (6)
Once ADHD is diagnosed, the facts surrounding the most effective treatment are complicated and
incomplete; contrary to some popular wisdom, behavioral treatments, alone or in combination
with low doses of medication, can be effective in the long-term reduction of core ADHD symptoms
and at improving many aspects of overall functioning. (7) Especially when a child occupies the zone
of ambiguity, different people will emphasize different values embedded in the pharmacological and
behavioral approaches. (8) Truly informed decision-making requires that parents (and to the extent
they are able, children) have some sense of the complicated and incomplete facts regarding the
diagnosis and treatment of ADHD.
Background
The US Centers for Disease Control estimates that approx-
imately 4.6 million (8.4%) American children aged 6–17
years have at some point in their lives received a diagnosis
of Attention-Deficit/Hyperactivity Disorder (ADHD). Of
these children, nearly 59% are reported to be taking a pre-
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scription medication [1]. Rates of stimulant use have been
growing fast in both the US and Europe [2-4]. Indeed, in
the last 10 years, Germany has seen a 47-fold increase [5].
But per capita stimulant consumption remains greater in
the US than in all of Europe. According to the Interna-
tional Narcotics Control board [6], "The per capita con-
sumption of methylphenidate in the US between 2003
and 2005 was approximately six times greater than that of
Australia, eight times greater than that of Spain, and 18
times greater than that of Chile" [7].
Not just school-age children are being treated with stimu-
lants. Stimulant use among preschool children is also
greater in the US than elsewhere: 0.44% of preschoolers in
the US are prescribed stimulants, compared with 0.05% of
preschoolers in the Netherlands, 0.02% of preschoolers in
Germany, and 0% of preschoolers in the UK [8].
The duration of treatment and complexity of the treat-
ment regimen is also growing. Before 2000, most children
treated for ADHD received short-acting drugs, during
school, for 1 or 2 years. Today many receive long-acting
drugs while in – and out – of school and the prevailing
recommendation from ADHD experts is to start medica-
tion early and to continue as long as medication is
needed. This suggests that, if they adhere to their regi-
mens, many American children diagnosed with ADHD
will receive far higher lifetime doses than similar children
in the past [9]. Even outside the US, a study of Dutch
youths showed that between 1995 and 1999, duration of
exposure to stimulants increased [10]. In addition, chil-
dren are more likely than in the past to have more than
one diagnosis and therefore to be taking multiple medica-
tions simultaneously [11].
Even without any further increase in the rate of stimulant
use (data from a federal survey suggest it may be leveling
off [12], whereas Health Management Organization pop-
ulation-based data show a slight but continuing increase
[4]) current usage rates raise a range of questions concern-
ing how we conceive of what we call ADHD in the US and
what are the most effective and appropriate ways to
respond to children who receive that diagnosis. Some of
these questions can be answered by more research and
better facts. Other questions turn on values. Some are
peculiar to the diagnosis and treatment of ADHD, but
most are questions that also arise in the diagnosis and
treatment of other behavioral and emotional disturbances
for which ADHD is a valuable case study [13].
The ADHD label refers to a heterogeneous set 
of phenomena
Some manifestations of the behaviors that today we call
symptoms of ADHD (inattention, hyperactivity, and
impulsivity) have been recognized as problematic for the
last 100 years – and, arguably, for much longer. Generally,
children are brought to their physicians because parents
or teachers are concerned that the child's behavior is pre-
venting him or her from functioning normally at home, in
school, or in other settings. In the majority of cases, teach-
ers are the first to suggest that a child might have ADHD
[14]. Initial assessments are often carried out by school
psychologists or clinical psychologists before a referral is
made to a physician. Workshop participant and educa-
tional psychologist Roy Martin noted: "In the vast major-
ity of cases, that physician is a pediatrician. In my
experience only 5 to 10% of cases result in a specialized
referral to a psychiatrist." Because physicians do not
observe the child's behavior in school or at home, they
must rely heavily on parents' and teachers' reports.
According to Martin, "Physicians are under pressure to try
to help, and therefore tend to respond to the felt needs of
parents and teachers." That response often takes the form
of a diagnosis, which physicians base on their training,
clinical judgment, and experience, as well as on diagnostic
tools and guidelines, such as those in the American Psy-
chiatric Association's Diagnostic and Statistical Manual
(DSM).
According to the fourth edition of DSM "the essential fea-
ture of Attention-Deficit/Hyperactivity Disorder is a per-
sistent pattern of inattention and/or hyperactivity-
impulsivity that is more frequent and severe than is typi-
cally observed in individuals at a comparable level of
development" [15]. Currently, to receive the diagnosis,
children must, before the age of 7, exhibit at least 6 core
symptoms and these symptoms must cause some impair-
ment in at least 2 settings (such as home and school),
although severe impairment in one setting can suffice
[16].
DSM IV lists 18 core symptoms of ADHD, which are
divided into 2 major behavioral domains: (1) inattention
and (2) impulsivity-hyperactivity. Among the 9 symp-
toms of inattention are: often makes careless mistakes,
often has difficulty sustaining attention in play or other
activities, and often does not seem to listen when spoken
to directly. Among the 9 symptoms of hyperactivity-
impulsivity are: often fidgets or squirms, often can not
stay seated, blurts out, and is impatient.
To bring conceptual order to this heterogeneous set of
behaviors, clinicians in the US currently distinguish
among 3 subtypes of ADHD: Predominantly Inattentive
Type, Predominantly Hyperactive-Impulsive Type, and
Combined Type. ADHD Not Otherwise Specified (ADHD
NOS) is a fourth category, and includes children who
exhibit fewer symptoms of inattention or hyperactivity-
impulsivity than children who meet the criteria for one of
the other 3 subtypes, but are nevertheless significantlyChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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impaired as a result of their symptoms. (More recently,
the usefulness of the conceptual order brought by the sub-
types model has been questioned [17].)
Findings from genetics and neurobiology have shed some
light on the genetic and neurological correlates of the
behaviors associated with ADHD [18,19]. For example, as
psychiatrist and workshop participant Laurence Greenhill
pointed out, researchers recently reported that a gene var-
iant, which codes for a dopamine receptor (the DRD4 7-
repeat allele) and was formerly thought to be a genetic
marker for ADHD, is also associated with thinning of the
cortex in regions associated with attention control [20].
These same researchers also found that among children
with ADHD, those with the DRD4 7-repeat allele eventu-
ally became more similar to normal subjects than did
ADHD children with a different genetic variant. (Brain
scanning research has also suggested that the brains of
some children with ADHD eventually "catch-up" with the
brains of unaffected children [21].) Findings such as the
one involving DRD4 may one day help clinicians to iden-
tify a class of children with ADHD who are likely, over
time, to outgrow their dysfunctional behaviors. But that
day has not yet come [19]. We simply do not yet have a
genetic test or a brain scan to diagnose ADHD, much less
its subtypes.
For one thing, geneticists today are grappling with the fact
that, in general, single gene variants by themselves are less
helpful in explaining the emergence of complex pheno-
types than was once hoped [22,23]. Moreover, neurobiol-
ogists are grappling with the fact that variations in single
neural circuits are less helpful by themselves in explaining
the emergence of complex phenotypes than was once
hoped [23]. Indeed, there is increasing agreement that, to
understand the etiology of phenotypes as complex as
ADHD, it will be necessary to investigate myriad genes,
multiple neural circuits, and myriad environmental varia-
bles, all interacting over time [24]. This phenomenologi-
cal and etiological heterogeneity begins to explain some
of the disagreement within – and beyond – psychiatry
about where the threshold lies between children who
should and should not receive the diagnosis.
The fact that symptoms are dimensional creates 
a zone of ambiguity and helps to explain 
disagreements about diagnosis
The creators of the DSM system of diagnosis had several
aims. They wanted to develop an algorithm that could
quickly and reliably identify individuals who needed
help. Such a neatly laid-out system would facilitate getting
reimbursement to deliver services. And the careful
description of symptoms was intended to help physicians
and researchers in different places feel confident that they
were indeed studying the same disease entity [15].
While the DSM system achieves those aims, it also entails
significant difficulties. First, a single diagnostic label –
ADHD – is used to name children who have different col-
lections and levels of symptoms and who suffer different
levels of overall impairment. Moreover, as workshop par-
ticipant and child psychiatrist Gabrielle Carlson sug-
gested, like many conditions, ADHD is expressed
differently in different children and it differs in severity
from mild, to moderate, to severe (some children with
severe ADHD require hospitalization).
Because ADHD does not have a single, simply identifiable
form, diagnosing it requires an observer's interpretation.
While many physicians will agree that one particular child
warrants an ADHD diagnosis and another child does not,
many children will occupy what we will call a "zone of
ambiguity." Physicians, teachers, and parents may well
disagree about whether children in the zone of ambiguity
exhibit the symptoms and suffer severe-enough impair-
ment from those symptoms to warrant the ADHD diagno-
sis. Increases in the rates of ADHD diagnoses and the use
of stimulant treatment have fueled the concern that too
many children in the zone of ambiguity are today given an
ADHD diagnosis rather than considered simply "differ-
ent" or "spirited," and that drugs are too often the treat-
ment of choice for these children.
The Introduction to DSM IV addresses some of this diffi-
culty by acknowledging that many psychiatric diagnoses
give labels to phenomena that are dimensional, not categor-
ical. Children with and without ADHD do not occupy
cleanly separate categories; rather, they occupy different
places on one or more dimensions (or continua or spec-
tra) of behavior. Bright lines do not separate children
whose attention, impulsivity, or activity levels are normal
from those whose are not (as with many disorders, includ-
ing hypertension and hypercholesterolemia). All children
lie somewhere on these behavior spectra and many will
fall in the zone of ambiguity. Despite the reminder in its
Introduction that psychiatric disturbances are dimen-
sional, DSM is a categorical system. Because DSM is so
important for diagnosis and reimbursement, users often
adopt its language and categories without recalling its lim-
itations.
According to several workshop members, yet another
problem is that, even though DSM explicitly states that
diagnoses should only be made if symptoms cause "clini-
cally significant impairment in social, academic, or occu-
pational functioning," clinicians sometimes base their
diagnoses on the presence of symptoms alone. In one
study, researchers reduced a 16.8% ADHD prevalence rate
to 6.8% by adding an impairment criterion [25]. While
impairment may be inferred from the fact that parents
made an appointment with a health professional, impair-Child and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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ment is not always carefully established by the physician
making the diagnosis. Reimbursement systems, which
usually require a DSM diagnosis, can also encourage clini-
cians to record a diagnosis of ADHD, even when the sever-
ity criteria are not fully met, in order to justify the
provision of services. A further problem of a symptom-
based diagnosis is that children with many symptoms but
less impairment may receive treatment and children with
fewer symptoms but greater impairment may go undiag-
nosed and untreated.
Our description of these complexities and the blurriness
of the lines is not to suggest that ADHD is not real. The
symptoms of ADHD can cause significant suffering in
children, families, and schools [26-28] and significant
costs to the health care system, education system, juvenile
justice system, and employers through parental work loss
[29]. We also do not mean to suggest that the DSM
descriptions and established diagnostic systems are hope-
lessly imprecise. Indeed, they are clear enough that raters
who are trained to use the same diagnostic system can
reach similar conclusions about prevalence rates. Rather,
we describe these complexities and the blurriness of the
lines to urge us to remember that ADHD is not a unitary,
simple thing. Like many other behavioral and emotional
disturbances, ADHD is a label for heterogeneous collec-
tions of dimensional behaviors that appear to have heter-
ogeneous causes.
To invoke a term that no fewer than three psychiatrists –
Michael First, Steven Hyman, and Benedetto Vitiello –
used at our first workshop, we need to avoid the "reifica-
tion" of the DSM categories. These categories are abstrac-
tions we have created, not entities we have discovered in
nature. Diagnostic categories can be useful tools to help us
talk about childhood behavioral and emotional distur-
bances, but we need to remember that they are tools cre-
ated by us. We – doctors, parents, teachers, and others –
set the threshold between behaviors and moods in need
of pharmacological or behavioral treatment and differ-
ences that should be left alone or dealt with in other ways.
One explanation for increased rates of diagnosis and stim-
ulant use, therefore, is that we are setting ever lower diag-
nostic thresholds. This explanation concerned many
workshop participants, including sociologist Peter Con-
rad and pediatrician William Carey. When they see data
documenting an increase in diagnostic and treatment
rates, they see a troubling decrease in societal tolerance of
the behaviors and impairment associated with the ADHD
diagnosis.
Other variables also help to explain why ADHD 
is diagnosed at different rates in different places
We have already observed that stimulant medications are
used at different rates in different countries. Specifically,
they are used at higher rates in the US than in culturally
similar places like Germany, the Netherlands, and the UK.
(Although not perfect, there is a strong correlation
between stimulant use and the ADHD diagnosis.) But
even within the US there is significant variation in diag-
nostic and treatment rates. Beyond the phenomenological
and etiological complexity and the zone of ambiguity we
described earlier, why would rates of ADHD diagnosis be
higher in some places than others?
Variations in diagnostic systems
At least when it comes to understanding the difference
between the rates at which ADHD is diagnosed in the US
and Europe, it helps to notice that clinicians in those two
geographical regions use closely related – but importantly
different – systems of disease classification. Whereas clini-
cians in the US currently use the DSM IV, clinicians in
Europe use the 10th edition of the World Health Organiza-
tion's International Classification of Diseases (ICD 10).
ICD 10 refers to Hyperkinetic Disorder (HD), whereas
DSM IV speaks of ADHD. And while DSM IV and ICD 10
use very similar lists of symptoms for ADHD and HD
respectively, their approaches to diagnosis are different in
some important ways. DSM IV requires a child to exhibit
only 6 symptoms in 1 of 2 broad domains (inattention or
hyperactivity-impulsivity), while ICD 10 requires a child
to exhibit 10 symptoms, including at least 1 in each of 3
domains (inattention, hyperactivity, and impulsivity).
Whereas DSM IV requires that some impairment be
present in more than 1 setting (school, home, etc.), ICD
10 requires that all criteria must be met in at least 2 set-
tings. In short, the DSM system casts a wider net than does
the ICD, so that "ADHD prevalence rates based on DSM-
IV are expected to be higher than those based on ICD-10"
[30]. Indeed, as workshop participant and child psychia-
trist Jörg Fegert noted, the DSM approach produces 3 or 4
times as many diagnoses as does the ICD approach [31].
The ICD and DSM approaches to coexisting conditions in
a single child are also importantly different. Under DSM,
a child can be diagnosed with ADHD and one or more
coexisting conditions, such as an anxiety, mood, or devel-
opmental disorder. According to ICD, however, if one of
those coexisting conditions is diagnosed, then HD cannot
be diagnosed.
However, even in the US, where all clinicians presumably
use the DSM approach, there is variation. As with other
disorders, community-based ADHD prevalence rates from
treatment data vary according to demographic factorsChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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such as age, gender, and race/ethnicity [32]. As workshop
participant and pharmacological epidemiologist Julie Zito
added, we have long noticed variation in rates of diagno-
sis and treatment by age and sex, with higher rates
reported in children aged 10–14 compared with children
aged 5–9 years, and higher rates in boys.
As with other disorders, there is also considerable regional
variation. Workshop participant and child psychiatrist
Regina Bussing pointed to Centers for Disease Control
data showing that the heaviest use of stimulants to treat
ADHD occurs in southern US states, followed by states in
the upper Midwest [33,34]. There is also variation within
states, and even within counties [35]. Geographic varia-
tion in treatment patterns is not uncommon in medicine
[36], and is ascribed to a number of factors, including var-
iation in levels of access, rates of occurrence, rates of serv-
ice utilization, treatment preferences, and clinical
practices [37,38].
Laurence Greenhill pointed to still other variables to help
explain international and regional variation in diagnosis
and use of prescription medication. Clinicians in different
places rely on different informants (e.g., parents alone, or
parents and teachers) and use different diagnostic guide-
lines [39] and diagnostic tools (e.g., the ADHD Rating
Scale-IV vs. the SNAP IV). Some geographic areas have vir-
tually no child psychiatrists, which means that primary
care physicians make almost all the ADHD diagnoses.
Physician specialty can affect diagnostic rates because pri-
mary care physicians are thought to be at risk for under-
and over-diagnosing ADHD [14,40].
Variations in home, school, and community environments
We also know that children's home, school, and commu-
nity environments can differ greatly, including their sleep
patterns, diets, physical exercise opportunities, and levels
of exposure to television and other media. Anthropologist
Sara Harkness cited studies she and child psychologist
Charles Super have conducted comparing Dutch and
American parenting styles: "The Dutch parents we studied
were very closely attuned to their children's state of
arousal and self-regulation, making sure that the child got
plenty of sleep and that the environment was not overly
stimulating. For Dutch parents, this was just a normal
aspect of good parenting, whereas for American parents
this approach might seem somewhat extreme, called for
only when the child is really out of control."
Harkness went on to note that Dutch schools are very con-
cerned with each child's ability to pay attention: "Virtually
every classroom I visited had two or three children's desks
that were placed away from the others (touching the
teacher's desk in a couple of cases), in order to help chil-
dren who seemed more distractible than others." Hark-
ness and Super also noted differences at a systems level;
children who had difficulty learning due to behavioral
problems were transferred to special schools, and the
school day included a lunch break long enough for chil-
dren to go home and spend time outside in unstructured
play. While the environmental causes of the behaviors
considered symptoms of ADHD are not well understood,
many workshop participants agreed that the child's envi-
ronment can influence the development of such behav-
iors.
In addition, because different cultures have what Roy Mar-
tin called "different local normative expectations," differ-
ent environments will be more or less tolerant of active,
distractible children, and will be more or less prone to see
impairment from those behaviors. To put the point in
diagnostic terms: observing the same behaviors at the
same rates in children around the world is one thing, but
these children will not meet the diagnostic criteria unless
they are also impaired by those behaviors in that culture.
People in some cultures are also more likely than people
in others to seek medical assistance and accept medical
(particularly pharmaceutical) treatments [41].
Many workshop participants were concerned that cultural
expectations in the US have grown intolerant of children
exhibiting the behaviors currently associated with ADHD.
Peter Conrad spoke of the "medicalization of underper-
formance," and psychiatrist John Sadler worried that
changes in expectations about the conduct of classroom
education and the pace of educational achievement make
it more likely that the active, distractible child will be con-
sidered a problem. That said, many workshop participants
agreed that children with the most severe forms of ADHD
would be impaired in virtually any culture, community,
or context.
Bearing in mind the myriad factors that can affect how dif-
ferent people interpret the same behaviors, and remem-
bering the phenomenological heterogeneity and
etiological complexity associated with ADHD as well as
the zone of ambiguity, it is hardly surprising that rates of
diagnosis are different in different places. More specifi-
cally, setting aside the debates about the particulars of the
DSM approach, we can see why there are concerns about
both over- and under-diagnosis.
Over- and Under-Diagnosis
The Great Smoky Mountain study examined the preva-
lence of serious emotional and behavioral disturbances,
including ADHD, in children in the western region of
North Carolina [42]. In the study, trained interviewers
applied DSM criteria, including the requirement for
impaired functioning, to a representative sample of 1,422
children. From these data, the researchers estimated thatChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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about 6.2% of children in the community met the criteria
for ADHD (a greater number exhibited one or more
ADHD symptoms but fell short of the diagnosis). The
study then looked at rates of stimulant use and found that
7.3% of children in the study had received stimulants at
some time during the 4 year study period. At first glance it
might therefore appear that slightly more children
received stimulants than met the DSM criteria for ADHD;
in fact, over 57% of those who received medication did
not meet the criteria.
Two factors explain the Great Smoky Mountain study's
findings. First, not all of the children who warranted an
ADHD diagnosis had received stimulants; 72.2% of the
children who warranted an ADHD diagnosis received
stimulants and only 22.8% of children who warranted an
ADHD-NOS diagnosis received stimulants. Second, 4.5%
of children who did not warrant an ADHD diagnosis nev-
ertheless received stimulants. While 4.5% is a small per-
centage, it is 4.5% of all the children in the study who did
not have ADHD, which is a large number. In terms of abso-
lute numbers, the study found that more children without
ADHD received stimulants than did children with ADHD.
The study concluded that in the community (as compared
to a rigorous research trial), a significant proportion of
children with ADHD do not receive stimulants and a sig-
nificant number of children without ADHD are pre-
scribed stimulants.
It is widely recognized that ADHD is over-diagnosed in
some affluent communities, where "local expectations"
are such that stimulants are just one more tool to promote
performance in "the Academic Olympics" [43]. Because
we, the authors of this document, assumed that children
living in poverty might be more likely to be judged unruly
and therefore be prescribed drugs like Ritalin, we came to
the workshop expecting to learn that ADHD is also over-
diagnosed in poorer children. We discovered that the
issue is a bit more complex. It is true that, in the US, access
to mental health services generally decreases with lower
economic status. Even though many poor children qualify
for publicly-funded programs, such as Medicaid, and
therefore for care that compares well with the care offered
to economically advantaged children, poor families often
under-utilize the services to which they are entitled
[34,44-46]. (The exception may be children in foster care,
who are almost all eligible for Medicaid, but whose utili-
zation rates are higher than other Medicaid-enrolled chil-
dren [47]). Add to this complexity that children in poor or
wealthy families may well be subject to different "local
normative expectations," and we can see how rates of
diagnosis might vary by economic status.
Different views about the proper goals of 
psychiatry and parenting lead to less or more 
concern about treating children in the zone of 
ambiguity
While there frequently will be agreement among experts
about whether to diagnose ADHD in children with very
mild and very severe impairment due to the behaviors asso-
ciated with ADHD, there always will be some children
whose symptoms and impairment place them in the zone
of ambiguity.
At least in part, views about where to set the threshold for
diagnosing ADHD will be a function of peoples' differing
conceptions of the proper goals of medicine in general or
psychiatry in particular. Some observers are not alarmed
by the tendency of medical institutions to treat ever more
problems that seem to have more to do with someone's
failure to meet social, cultural, or educational expecta-
tions than with a failure of physiological function. Others,
like sociologist and workshop participant Peter Conrad,
who are often alarmed by this tendency, label it medical-
ization and see both diagnosis and treatment as "social
control for deviant behavior" [48].
Sharing the medicalization concern, workshop partici-
pants like pediatrician William Carey emphasized that we
need to get better at accepting that children come into the
world with different temperaments (or behavioral styles)
[49]. According to Carey, if we better understand that
"normal" includes a wide variety of temperaments, we
will also understand that temperamental differences do
not necessarily entail either impairment or harmful dys-
function. We then will be quicker to accommodate such
differences and slower to treat them with a branch of med-
icine. Carey is not simply urging caution about using drugs
to alter a child's temperament; he is urging caution about
using any means to shape what he urges us to view as nor-
mal temperamental differences. He is equally concerned
about the overuse of behavioral interventions, which he
thinks should be reserved for responding to problematic
behaviors (e.g. ignoring teacher requests) rather than prob-
lematic behavioral styles  (e.g. a restless temperament)
[50].
The authors of this report, and many members of the
workshop, share Carey's commitment to tolerating and
even affirming a diversity of temperaments. And we recog-
nize that this commitment is, to some extent, rooted in an
intuition about our appropriate attitude toward ourselves
and the world. It is an intuition about the value of accept-
ing and affirming children "as they are" and allowing
them to unfold in their own way, as opposed to seeking to
transform them into our vision of how they ought to be
[51]. When we speak of Carey's "commitment," and sug-
gest that it grows out of an intuition about what is valua-
ble, we are not suggesting that it is unimportant. We mean
only to recognize that, as important as it is, the concernChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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about medicalization does not grow out of reason alone
and will not be shared universally. We would, however,
emphasize that people who are not alarmed by medicali-
zation also proceed from intuitions about what is valua-
ble.
Indeed, other members of our workshop, such as psychi-
atrist and neurobiologist Steven Hyman, introduced a dif-
ferent intuition about how to respond to children in the
zone of ambiguity. He suggested that, whatever the histor-
ical goals of medicine, if we can use it to reduce children's
suffering and enhance their agency, perhaps we should.
He, too, is aware of the importance of letting children be
"as they are," but he emphasizes that parents are also
obliged to shape their children and improve their chances
of living a good life in the culture in which we live. If a
choice has to be made between promoting a child's flour-
ishing in our world and accommodating and affirming
her temperamental differences, Hyman and many others
might choose the former.
Neither the authors of this document nor anyone else has
the "view from nowhere" that would be required to pro-
nounce which of those positions is right. We seek only to
emphasize that those who would set the threshold for the
diagnosis of ADHD low and those who would set it high
both appeal to intuitions and values. Neither side appeals
to facts alone.
There is nothing "mere" about social 
constructions
Because the ADHD diagnosis involves interpretations and
values, and because the rates of ADHD diagnosis vary
from place to place, it has been argued that ADHD is not
a real disorder, but is instead a cultural or social construct
[7]. A recent meta-analysis that examined studies of prev-
alence rates in different countries, and the published com-
mentaries that accompanied it, grappled with just that
charge.
In 2007, Guilherme Polanczyk et al. published a widely
cited article that analyzed much of the extant literature on
the prevalence of ADHD/HD [30]. They found studies
reporting prevalence rates ranging from a low of 1% to a
high of 20%. But in their analysis they argued that, if, in
addition to taking into account the geographic location of
the study, one takes into account the methodological dif-
ferences among the investigators – the different diagnostic
criteria that the studies used, who reported on the symp-
toms, and how much impairment was required for diag-
nosis – the worldwide prevalence of ADHD/HD is 5.3%.
In a commentary accompanying the Polanczyk study, Ter-
rie Moffitt and Maria Melchior wrote that the study shows
that ADHD is "a bona fide mental disorder (as opposed to
a social construction)" [52]. We would offer a different
interpretation, one that Olavo Amaral in fact offered in a
letter responding to the Moffitt-Melchior commentary.
Amaral wrote: "The concept of a disorder and its diagnos-
tic criteria are social constructions by definition, and the
fact that a group of symptoms has a constant geographic
prevalence has little to do with what leads these symp-
toms to be considered a diagnostic entity" [7]. As he
points out, twin pregnancies, for example, are largely
equally prevalent across the world, but whereas having
twins can still be a source of shame in some South Amer-
ican countries, it tends to be a source of pride in North
America. The same phenomenon is "constructed" differ-
ently in different places. Workshop participant and child
psychiatrist Benedetto Vitiello put the same point in sub-
tler terms: even where culture does not affect the fre-
quency and presentation of a certain behavior, it certainly
influences the local interpretation of that behavior. It may
be that a group of raters trained to apply DSM criteria
would diagnose children with ADHD at about the same
rate in different countries. But such a finding would not
tell us that these children were "really" disordered if some
of them are nevertheless considered normal enough (i.e.,
not disordered) in their own countries. Determining
which children are "really" disordered will always be in
part a function of the culture in which the child lives.
Polanczyk et al.'s response to Amaral's letter is worth not-
ing [53]. In emphasizing the similarity in the prevalence
of ADHD across cultures, they said that they intended to
help reduce the stigma associated with the ADHD label.
They assumed that in establishing the fairly uniform prev-
alence of ADHD behaviors across cultures they were dem-
onstrating the reality of the disorder. In defeating the
claim that ADHD is "merely" a social construction, they
aspired to get treatment to children who need it – espe-
cially, they emphasized, poor children. Second, they
argued that, even though different cultures may interpret
certain universal phenomena differently, some cultures
are more correct in their constructions. To make this
point, they suggest the example of obesity: Yes, it may be
constructed "positively" in some Pacific Island cultures
and "negatively" in North America, but "the link between
obesity and several adverse outcomes is well established,
supporting its validity as a medical condition."
While participants in our workshop would argue that we
do not understand the causes and effects of the behaviors
associated with ADHD as well as we understand the
causes and effects of obesity, many accepted that the
behaviors associated with ADHD appear in children
across the globe, whether at the same or slightly different
rates. And all believe that we have a moral obligation to
help children who suffer from harmful dysfunction as a
result of these behaviors – especially those who currentlyChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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are underserved. But where to set the threshold between
normal variation and ADHD (or obesity) that deserves
treatment is up to human beings, whose perspectives and
values will differ. The threshold is not inscribed in nature,
as is made clear by the fact that two reasonable and widely
used diagnostic systems, DSM IV and ICD 10, draw it at
different places.
Recognizing that it is up to human beings operating in
particular cultural contexts to decide where to set the
threshold between disordered and normal behavior does
not commit us to viewing ADHD as "merely" a social con-
struction. ADHD is  a social construction; what it is
depends on our interpretations of natural phenomena.
But there is nothing "mere" about it. Social constructions
are as real as any other feature of our lives.
Once we accept that there is no clear line between children
with and without ADHD, and that this line must be artic-
ulated by physicians, parents, teachers, and others in soci-
ety, we still need to ask, What should we do to help
children who we deem to be impaired by their ADHD
behaviors?
The facts surrounding the most effective 
treatment of ADHD are complicated and 
incomplete
There are many possible responses to the behaviors asso-
ciated with ADHD, from changing the child's sleeping and
eating patterns, to classroom interventions, to medica-
tion. Only some of these responses require the help of
medical professionals. Here we refer to all medical
responses as "treatments." The two main treatments
offered by health professionals to children diagnosed with
ADHD are medications and behavioral therapy. The stim-
ulant Ritalin (methylphenidate) was approved by the FDA
to treat the symptoms of ADHD in children in 1955 and
behavioral treatments have been developed and studied
over the past several decades [54]. Of the two treatments,
stimulants are administered most frequently [39].
In 1992, the National Institute of Mental Health and the
Department of Education cosponsored a randomized
clinical trial to compare the long-term efficacy of these
two treatments. Over the course of 14 months, researchers
observed children with ADHD who were being treated
with either: (i) the researchers' carefully crafted regimen of
medication; (ii) intensive behavioral  treatment (with
responsibilities for the child, parents, teachers and
teacher-aids, and therapists); (iii) combined  medication
and behavioral treatment; or (iv) standard community
care (i.e., whatever providers in that child's community
offered to children with ADHD).
The initial, highly influential conclusions of this Multi-
modal Treatment Study of Children with ADHD (MTA)
were published in 1999. After 14 months, MTA investiga-
tors concluded that, while all 4 treatment options showed
sizable reductions in symptoms, their finely tuned regi-
men of medication alone was superior to the other 3 arms
of the study for treatment of ADHD symptoms [55]. The
MTA group wrote: "If one provides carefully monitored
medication treatment similar to that used in this study as
the first line of treatment, our results suggest that many
treated children may not require intensive behavioral
interventions" [55].
Following publication of the initial MTA findings, enthu-
siasm for drug treatment appeared in high-profile practice
guidelines (including those from the American Academy
of Pediatrics [56] and the American Academy of Child and
Adolescent Psychiatry [57]). The consensus seemed to
have become that drugs alone are an effective treatment
for ADHD, with behavioral approaches a possible
adjunct.
However, according to some of our workshop partici-
pants, including psychologists William Pelham and
George DuPaul, the drugs-first approach is mistaken. They
point out that when MTA followed-up with their partici-
pants, 22 months after the study had ended, combined
and behavioral treatments were as effective as medication
alone at reducing ADHD symptoms. Perhaps more
importantly, they (and William Carey) argue that reduc-
tion of core ADHD symptoms alone is not sufficient to
determine effectiveness [58].
While it was clear to the MTA researchers that at 14
months those children taking their carefully managed
stimulant regimen exhibited the greatest reduction in
ADHD symptoms, they also recognized at that time the
benefits of combination (drug and behavioral) therapy. In
a press release accompanying the initial findings, NIMH
wrote: "for some outcomes that are important in the daily
functioning of these children (e.g., academic perform-
ance, family relations), the combination of behavior ther-
apy and medication was necessary to produce
improvements, and families and teachers reported some-
what higher levels of consumer satisfaction for those treat-
ments that included behavioral therapy components.
Furthermore, the combination program allowed children
to be treated over the course of the study with somewhat
lower doses of medication" [59]. The study also found
that for children with coexisting conditions, combined
treatment was superior at controlling ADHD symptoms. It
seems to us, the authors, that these findings were not
given sufficient attention when the initial MTA findings
were published.Child and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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Even if one focuses only on improvement in ADHD symp-
toms, later reports from the MTA study throw some doubt
on the superiority of medication-only treatment. When
MTA researchers followed up with the children nearly 2
years after the study ended, they found that those who had
originally been assigned to the medication arm of the
study no longer outshone those in the other three arms. In
fact, all three groups showed similar levels of ADHD
symptoms. "By 36 months, none of the randomly
assigned treatment groups differed significantly on any of
the five clinical and functional outcomes" [60].
Pelham and DuPaul also argue from their own data and
experience that combined medication and behavioral inter-
ventions may produce significantly more improvement in
key domains of daily life functioning than medication
alone, and that behavioral treatment can make it possible
to use lower "doses" (or intensity) of the drugs [61,62].
Lower doses of medication have fewer side effects and a
better safety profile. In response to concerns about the
financial and time commitment for behavioral treatment,
they point out that some families report significant
improvements with less intensive behavioral treatment
than was used in the MTA study, and that behavioral treat-
ment can be tapered off; after an initial intensive period,
children, parents, and teachers learn new skills and behav-
ioral treatment is incorporated into their lives and work,
whereas it is usually assumed that medication will need to
be taken long-term.
In addition to behavioral treatment's success at improving
ADHD symptoms, Pelham and DuPaul cited data show-
ing that parents and children generally prefer treatment
regimens that include, or are focused on, behavioral inter-
ventions [63]. There is also evidence that behavioral inter-
ventions are more likely than pharmacological ones to
lead to permanent improvements in aspects of a child's
overall functioning (more on this below). In fact, Pelham
and DuPaul are so impressed by the efficacy of behavioral
treatments that they argue for using them as first line treat-
ment for many children with ADHD. On this approach,
treatment of children with mild or moderate ADHD
would begin with behavioral treatment (at home and
school). Physicians would, only as necessary, add low
doses of medication.
The medication approach
To begin to understand the apparent discrepancy between
the initial findings of the MTA and current common prac-
tice, on the one hand, and the latter findings of the MTA
and Pelham and DuPaul on the other, it helps to recall
how stimulant medications work. Stimulant drugs, like
many medications used in pediatric psychiatry, can
reduce the severity of, or even eliminate, symptoms. But
they do not "repair" or "treat" the underlying causes in the
brain of those symptoms. Stimulants can reduce a child's
inattentiveness and hyperactivity, but can not by them-
selves teach the child to control his or her attention or
activity levels. Further, relief of symptoms does not neces-
sarily mean improvement in the overall functioning of the
child. It is of paramount importance to recognize that
how one defines efficacy – whether one measures only
reduction in symptoms or also improved academic
achievement, improved peer and family relations,
improved classroom behavior, etc. – can determine which
treatments one considers effective. Treatments that
improve symptoms alone do not satisfy those who, like
Pelham, believe that "minimization of impairment in
daily life functioning and maximization of adaptive
skills" ought to be the goal.
Some workshop participants suggested that by reducing
symptoms, stimulants should make it easier for children
to "learn how to restrain their impulses" or "get ready to
learn behaviorally." However, as an empirical matter, as
soon as the drug treatment stops, many children return to
the behaviors of their original, un-medicated state. As Ste-
ven Hyman observed, "cognitive control of behavior
doesn't get a boost from these months or years on medi-
cation." (This finding did not surprise some workshop
participants, who pointed out that a diabetic child who
stops taking insulin returns to an uncontrolled diabetic
state.)
Importantly, it is not yet established that a reduction in
ADHD symptoms necessarily leads to the hoped-for
improvements in academic achievement [64]. Medication
can "produce acute, short-term improvements in on-task
behavior, compliance with teacher requests, classroom
disruptiveness, and parent and teacher ratings of ADHD
symptoms" [65]. And, as Benedetto Vitiello pointed out,
there is evidence that stimulants help to improve school-
work accuracy and productivity. But despite these
improvements, Vitiello said that researchers do not cur-
rently have sufficient data to conclude that improving
attention to accuracy or productivity translates into long-
term improvements in academic achievement (under-
stood as improvements in standardized test scores or ulti-
mate educational attainment) [64]. Although symptom
reduction may be a relief for the teacher, child, and par-
ent, George DuPaul also agreed that it does not usually
translate into long-term improvement in academic per-
formance.
No one is quite sure why a reduction in ADHD symptoms
does not translate into long-term improved academic
achievement. As a partial explanation, Pelham noted that
while attention and productivity are necessary for learn-
ing, they are not sufficient (attention, productivity, and
learning are different processes). Other workshop partici-Child and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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pants added that a reduction in ADHD symptoms cannot
erase any learning disability that a child might have nor
make a child more intelligent. One thing, however, is
clear: parents, teachers, and physicians all deserve to know
the state of the evidence.
In addition to concerns about long-term efficacy, worries
about adverse drug effects persist, even though stimulants
have been used for more than half a century. According to
several reports [66], long-term stimulant use can slow
physical growth by 1.2 cm per year [67] and slightly
increase blood pressure and heart rate, although the clin-
ical implications of these increases are unclear [68]. Rare
instances of sudden deaths have been reported in children
receiving stimulants; however, no causal inference has
been drawn from these reports because a high proportion
of the children also had structural heart abnormalities
[69]. Long-term use of stimulants can also increase insom-
nia or decrease appetite [70]. While most available data
do not suggest that therapeutic use of stimulants increases
the risk for subsequent drug abuse [71], all current studies
have methodological limitations that prevent drawing a
definitive conclusion on the link between stimulants and
substance abuse. Clearly, more research is needed on the
long-term effects of stimulants on the developing brains
of the ever-younger children who receive them.
Behavioral approaches
The potential for adverse drug effects, no matter how
small, is one reason why some people invoke the princi-
ple of "do no harm" – and urge beginning with behavioral
treatments. Proponents also point to multiple studies
showing that behavioral treatments are more effective
than drugs alone at improving the overall functioning of
children with ADHD [72].
Advocates for "behavioral treatments" are referring to a set
of interventions that include teaching parents how to bet-
ter parent a child with an ADHD diagnosis, teaching
teachers how to better teach children with ADHD, and
helping children take responsibility for monitoring and
managing their own behavior. Parents and teachers post
rules, adjust workloads, provide choices, reinforce good
behavior, and offer special tutoring [73]. The MTA study
described above showed that this kind of behavioral treat-
ment significantly reduced the symptoms of ADHD and
improved some aspects of the child's overall functioning
(with and without low doses of concurrent medication)
[55]. Nearly two years after MTA's behavioral treatment
finished, there had been no loss in its effectiveness and the
majority of children who received it were still unmedi-
cated [60]. Behavioral treatments show an effect even after
the formal therapy ends because, in theory and to a sur-
prising extent in practice, parents, teachers, and children
continue to implement what they learned. (Like dieting
and exercise to combat obesity, behavioral treatments
only continue to work if individuals continue to follow
the new behaviors.) However, while behavioral treat-
ments are associated with improvements in aspects of
overall functioning, such as parent-child interactions and
a reduction in oppositional-defiant behavior, their impact
on long-term academic achievement has not been care-
fully studied [64].
While there was enthusiasm among many workshop
members for using behavioral interventions as the first
line of treatment – and when necessary for combining
behavioral and pharmacological approaches to maximize
functional improvements – there was also a keen sense of
the challenges inherent in behavioral approaches. As child
psychiatrist Gabrielle Carlson pointed out, because they
require a lot of parents, behavioral interventions can be
difficult for some parents to carry out, including those
who themselves struggle with ADHD.
In a similar vein, Carlson, Martin, and Super each empha-
sized that behavioral approaches may impose more
demands on already overburdened teachers, suggesting
that making behavioral treatments effective will mean
addressing education at a systems level, rather than sim-
ply at the level of the individual teacher and student. Mar-
tin also expressed concern about whether it is realistic to
hope to "scale up" the behavioral programs described by
researchers like Pelham. Sara Harkness granted that for
behavioral treatments to be adopted by parents and teach-
ers – and she is confident that they can be – "a change in
mindset is required, and structural changes in school
schedules as well as family routines should be brought
into the discussion."
During our discussion of the costs of behavioral
approaches, Pelham argued that behavioral approaches
would actually save money in the long run because the
changes they bring about are long-lasting. When com-
bined with medication, behavioral treatments can also
allow for lower doses of medication to be used, thereby
saving on medication costs. He also argued that, while the
behavioral treatment used in MTA was extremely inten-
sive, lower "doses" of behavioral treatment will suffice for
many children with mild to moderate ADHD.
Many workshop participants agreed that failing to
respond to ADHD – whichever treatments are offered –
also carries costs, to the health care system for associated
injuries and medical problems, to the education system,
and to the juvenile justice system [29]. Acknowledging the
costs of ADHD, however, does not tell us what is the most
effective, including most cost-effective, means of treating
or otherwise responding to children with an ADHD diag-
nosis.Child and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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Finally, pediatrician Kelly Kelleher asked the group to
consider, quite aside from cost, how very difficult it is to
get from the state-of-the-art treatments administered by
pediatric psychiatrists working in research settings to the
treatments that average children receive in community
practices. As he reminded us, it would be irresponsible to
forget the size of the gap between "academic expectations
and practice in the trenches."
The pharmacological and behavioral approaches 
emphasize different values
Children who are impaired by the symptoms of ADHD
deserve access to thoughtful, evidence-based treatment.
While there is some agreement about clear-cut cases
(where no medical treatment need be offered, relying
instead on changes to the home or school environment,
or where drug and behavioral treatments should be
offered), it is inevitable that physicians will sometimes
disagree about how to respond. Just as values play an ine-
liminable role in reaching decisions about where to set the
threshold for the diagnosis of ADHD, so too are they
implicated in decisions about which treatment would be
best for a particular child [74].
As mentioned above, some of the value differences that
arose in discussion of the proper goals or purposes of child
psychiatry in general, also arose in discussion of the spe-
cific means used to treat many childhood disturbances:
psychotropic medications. Pharmacological epidemiolo-
gist Julie Zito argued that some children will simply out-
grow and learn to control negative behaviors and
therefore that we should sometimes "let nature take its
course." Other workshop participants, such as pediatri-
cian Lawrence Diller, argued that when choosing between
drugs and behavioral interventions, we should begin with
those behavioral interventions that have proven efficacy.
Zito's and Diller's preferences can be explained by con-
cerns about the side-effects and safety of drugs, as well as
their long-term efficacy. But we think that they also may
be explained by examining the different values expressed
in drug treatments on the one hand, and behavioral treat-
ments on the other.
Whereas medications tend to emphasize the value of effi-
ciency (insofar as they are quicker acting and, in the short-
term, cheaper), behavioral interventions tend to empha-
size the value of engagement (insofar as they require the
child to engage with parents, peers, teachers, or therapists,
and they require these others to engage with the child and
with his environment) [75]. Because they do not seem to
locate the "problem" in the child's body, but instead in
the interaction between the child and his home, school,
and social environments, behavioral interventions
prompt us to notice the importance of the child's environ-
ment and take steps to improve it. They also can help the
child learn to think of himself as a moral agent, as some-
one who can learn how to change [75].
Critics of pharmacological means have also raised the
concern that stimulants separate or alienate the child from
who he really is, thereby undermining or diminishing his
authenticity [76]. Workshop participant and psychologist
Ilina Singh is investigating the authenticity concern by
interviewing children and their parents about the ADHD
diagnosis and stimulant medication [77]. However, her
preliminary results show that parents and children do not
say that medication alienates the child from himself, but
rather that by helping the child to overcome his "inner
badness," the drugs empower him. (Or, as the language of
authenticity would have it, drugs allow the child to
become "who he really is.") Singh's unfolding work is
offering a complex account of how parents and children
speak about the relationship between the self, their
ADHD diagnosis, and medication.
Like some of the parents and children Singh interviewed,
some members of our workshop also tend to be impatient
with the concern that drugs will alienate us from ourselves
or undermine our agency. They even invoked Gerald Kler-
man's phrase "pharmacological Calvinism" [78] to sug-
gest that opposition to pharmacological interventions is
motivated by an unreflective, quasi-religious commit-
ment to the value of suffering. According to the "pharma-
cological Calvinism" charge, it does not matter which
means we use to reduce problematic behaviors. What
matters is the end or goal of the intervention: insofar as
drugs and behavioral interventions both aim at changing
brain wiring, there is no good reason to automatically pre-
fer one over the other.
It is important to notice that people who are more and less
comfortable using drugs to treat ADHD do not so much
hold altogether different values as they emphasize differ-
ent values [51]. Both sides want to use the treatment that
is best for the child and her family. But just as determining
what is "genuine" impairment (and therefore who war-
rants the ADHD diagnosis) and what is "merely" a tem-
peramental difference (and therefore does not require
diagnosis or treatment) involve values, so too does decid-
ing whether a drug, a behavioral treatment, or some other
response is best for a particular child. We see no "crisp"
[79] solution to disagreements that emphasize different
values. Instead, we must accept a certain amount of varia-
tion, uncertainty, and ambiguity when it comes to diag-
nosing and treating children who exhibit the symptoms
associated with ADHD.Child and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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Truly informed decision-making requires 
grappling with complicated and incomplete facts 
regarding diagnosis and treatment
For the many reasons we have already discussed (includ-
ing phenomenological heterogeneity; etiological com-
plexity; differences in diagnostic and reimbursement
guidelines and tools; and differing cultural and educa-
tional expectations of children), there always will be a
zone of ambiguity: a range of cases where it is just not
obvious whether we should consider a given child as dis-
ordered and in need of treatment or temperamentally dif-
ferent and in need of toleration and adaptation, or
something in between. How we conceive of that child is
important, insofar as labeling her as disordered will entail
responding to her first with treatment, and labeling her as
different will entail responding to her first by placing her
into, or creating for her, a more welcoming environment.
We emphasize "first" because these two responses are not
mutually exclusive. In those cases where it is decided that
treatment is appropriate, there may be reasonable differ-
ences of opinion about whether to begin with drugs,
behavioral interventions, or a combination.
Gabrielle Carlson suggested that the severity of a child's
impairment can guide treatment choices. Children with
very mild impairment might best be viewed as needing tol-
erance of, and adaptation to, their temperamental differ-
ences rather than drugs or intensive behavioral treatment.
Children with mild ADHD might benefit from classroom
adaptations, improved structure and consistency at home,
and some teaching of organizational skills, but should
only be offered a stimulant if the behavioral interventions
fail. Children with moderate ADHD should receive behav-
ioral treatment and might warrant drug treatment during
school hours. Children with severe  ADHD should be
offered intensive behavioral treatment and a drug treat-
ment. Carlson's suggestion emphasizes that decisions
about whether to treat and how will vary depending on
assessments of the severity of the child's symptoms and
impairment. Her suggestion, of course, does not obviate
the need for these thresholds and categories.
But how should we make decisions in individual cases? In
short, parents – and, the child to the extent that she is able
– with input from medical, behavioral, and educational
professionals, should consider the relevant complexities
and make decisions that are as truly informed as possible.
As psychiatrist Jefferson Prince pointed out, families have
to recognize that, because our understanding of these
behaviors and what works to treat them is evolving, many
families will to some extent always be engaged in an
experiment with their doctors to understand their child's
impairment and to determine how best to respond to it.
Though it may be difficult or unsettling for families and
even physicians to face such ambiguity and uncertainty,
the principle of respect for persons requires physicians to
help families do exactly that.
Given that many children can understand and form views
about their diagnosis and treatment, should they have a
say about which treatment they receive? The answer likely
depends on the age and maturity of the individual child.
According to workshop participant Jörg Fegert, whereas
school age children say they want to be informed by their
parents about decisions that directly affect them, adoles-
cents say they want to be actively involved in the decision
making process. Getting assent from school-age children
and informed consent from adolescents under some cir-
cumstances squares well with the 2001 recommendations
by the American Academy of Pediatrics [80] and with
work done by other researchers from childhood studies,
such as Priscilla Alderson [81]. Nonetheless, we recognize
that the questions regarding the role of children in deci-
sions about their own treatment – especially for emo-
tional and behavioral disturbances where the child's very
capacity to understand their disorder may be at issue –
require much more research and reflection, and will likely
vary according to the maturity, insight, and abilities of the
individual child. At least one workshop member, Gabri-
elle Carlson, lamented that, whereas we do know some-
thing about how parents feel about treating children for
ADHD [82], we know little about what children feel about
their own treatment. Fortunately, that situation is chang-
ing [77,83].
Letting families decide hard cases is not a magic bullet.
Parents, whether they are together or separated, can disa-
gree about which response is best. Our workshop partici-
pants did not discuss at length what should happen when
parents, parents and children, or families and physicians
reach different conclusions about diagnosis and treat-
ment. What little discussion we had on this topic was
inconclusive. For example, one physician said that he
would treat a child only if both parents agreed, while
another physician said he would treat even if only one
parent requested it.
All agreed, however, that making decisions that are as
truly informed as possible requires good information
about the child's symptoms and impairment as well as
about the impact of treatments, which can take time. To
save time, Kelly Kelleher suggested gathering detailed
information from multiple sources about a child's symp-
toms and impairment and about the day-to-day efficacy of
treatments through cell phones, web-interfaces, and other
technologies. With technology, a team of mental health
providers can gather more detailed information than they
would access through one-on-one interviews, make better
diagnoses, and more carefully monitor children's reaction
to treatment. Technology can even remind children orChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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parents to take medications [84]. Kelleher also urged us to
abandon our nostalgia for solo practitioners and appreci-
ate the benefits of having patient information shared
across large, integrated, technologically savvy systems of
care. He argued that the privacy of sensitive medical infor-
mation can be protected while nevertheless enabling pro-
viders to nimbly and quickly communicate with children,
their families and teachers, and to follow a child's
progress.
Clearly, making decisions that are as informed as possible
also requires access to information that is as objective as
possible. While workshop members are keenly aware of
the great good that pharmaceutical companies do, they
are also profoundly concerned about the threat that
industry funding of research and relationships between
industry and researchers pose to the creation and dissem-
ination of scientific information [85]. The risk that drug
companies might suppress or delay release of data from
trials that reflect badly on their product or subtly influ-
ence the judgment of those charged with designing or
interpreting data was deeply concerning to some work-
shop participants, as was aggressive marketing to health
professionals and consumers of pharmaceuticals and the
conditions they treat. Any entity or practice that dimin-
ishes the quality of the information available to profes-
sionals and patients also diminishes the ability of families
to reach decisions that are as informed as possible.
Finally, workshop participants returned to a basic issue
that, like others discussed above, is not unique to ADHD.
Many workshop participants believe that there is a system-
wide push towards the diagnosis of mental disorders and
the use of drugs in preference to behavioral therapy
because drugs are easier to administer and, perhaps
wrongly, considered cheaper. Much like other chronic ill-
nesses in the US, ADHD is often addressed in primary care
settings where practitioners are under pressure to see
many patients quickly and face restrictions on what third-
party payers will reimburse. Not only is a diagnosis
needed in order to access treatments, but payers often
place limits on the number of therapy sessions that will be
reimbursed, but not on the number of prescriptions. As
workshop participant John Sadler put it: "The economics
are simple: we prescribe more drugs in the US because
[third-party payers believe] they are cheaper than costly
behavioral interventions."
Given the prevalence of ADHD, philosopher and work-
shop participant Bonnie Steinbock also wondered
whether a public health approach, which sought to under-
stand the underlying causes and focused on prevention,
might be warranted. Steinbock argued that an analogy
might be made with obesity, rates of which have soared in
the past few decades. If we understood better the causes of
ADHD, we would not simply focus on diagnosis and
treatment, but also on policy changes. That is, she brought
us back to what Harkness and Super call the child's devel-
opmental niche [86], asking us to focus on what can be
done at a systems level to improve children's environ-
ments so that they are either less likely to develop the
behaviors associated with ADHD or are more likely to
flourish despite those behaviors.
Concluding observations
1. The ADHD label refers to a heterogeneous set of symp-
toms that cause impairment.
a. Until we have valid biological markers, diagnosis will
depend upon observers' interpretations of children's
behavior.
2. The fact that symptoms are dimensional (rather than
categorical) helps explain disagreements about diagnosis.
a. Most children will express some of the behaviors asso-
ciated with ADHD, but not all children are impaired as a
result.
b. While it will sometimes be clear to virtually all observ-
ers that one particular child is impaired and another child
is not, the dimensional nature of behaviors means that
there will be a large zone of ambiguity: i.e., a significant
number of cases in which reasonable people will interpret
the same child's behavior differently.
3. ADHD is diagnosed at different rates in different places.
a. Variation in rates of diagnosis is due to many variables,
from different professional systems of diagnosis (e.g.,
DSM vs. ICD) to different styles of parenting and expecta-
tions of children.
b. Using DSM IV criteria, ADHD is both under- and over-
diagnosed.
4. People hold different – and reasonable – views about
the proper goals of psychiatry and parenting, and thus
worry less or more about treating children in the zone of
ambiguity.
5. There is nothing "mere" about social constructions.
a. To recognize that there is no bright line written in
nature between impaired and unimpaired children – to
recognize that it is up to human beings to choose who
should receive a diagnosis and who should not – is to
acknowledge that ADHD is "a social construction." But
acknowledging that does not make us diagnostic nihilists;
rather, it means we understand that because nature doesChild and Adolescent Psychiatry and Mental Health 2009, 3:1 http://www.capmh.com/content/3/1/1
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not show us where that line is, it is our weighty responsi-
bility to decide where to draw it.
6. The facts regarding different treatments are complicated
and incomplete.
a. When a diagnosis is made, the facts surrounding the
most effective treatment strategy are, unfortunately, less
certain than caring physicians and distressed families
would wish. For one thing, "efficacy" can be defined in
different ways, from reduction in symptoms to improve-
ment in academic achievement and peer and family rela-
tions. Recent research suggests that while stimulant
medication is often effective in the short term at reducing
the core symptoms of ADHD it is not always effective in
the long term at improving a child's overall functioning.
Moreover, it has been shown that behavioral treatments,
alone or in combination with low doses of medication,
can be effective in the long term at reducing the core
symptoms of ADHD and at improving many aspects of
overall functioning.
7. People hold different – and reasonable – views about
the proper means for psychiatry to employ in the treat-
ment of ADHD.
a. People who favor either medication or behavioral treat-
ment can disagree about both the facts – which treatment
most effectively reduces symptoms and improves overall
functioning – and values – which treatment most effec-
tively respects individual temperaments and improves
children's lives.
8. Truly informed decision-making
a. Parents (and to the extent they are able, children)
should be provided with the facts they need to make truly
informed treatment decisions. Because many children will
fall within the diagnostic zone of ambiguity, and because
choosing a treatment plan requires grappling with uncer-
tain facts about efficacy and long-term effects as well as
with important values, that process will sometimes be dif-
ficult. To be truly informed, that process must be as insu-
lated as possible from financial interests.
b. The current US health care and education systems tend
to favor pharmacological treatments, which are believed
to be less expensive than behavioral treatments. Scaling
up behavioral approaches would indeed require initially
costly changes in classrooms, schools, and the education
system, as well as in reimbursement policies. It would also
entail opportunity costs to parents and children, who
would need to work at learning new behavioral
approaches. Alone or together with pharmacology, behav-
ioral approaches may nonetheless more effectively
improve overall functioning than pharmacological treat-
ments alone.
c. Rather than debating whether medication is good or
bad in itself, we should continue the dialogue about how
to introduce changes in families, classrooms, schools,
health care systems, and cultures so as to reduce the inci-
dence of ADHD behaviors and reduce the likelihood that
children who do have those behaviors will be impaired.
When families consider it necessary to enlist medical
assistance in treating impairing behaviors, they should be
carefully informed of the benefits and limitations of med-
ication and behavioral therapy.
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